Drug-induced corneal epithelial changes

Survey of Ophthalmology

Volumn 62, Issue 3, 2017, Pages 286-301

  Raizman, Michael B ^a   Hamrah, Pedram ^a   Holland, Edward J ^b   Kim, Terry ^c   Mah, Francis S ^d   Rapuano, Christopher J ^e   Ulrich, Roger G ^f  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d SCRIPPS CLINIC   (United States)

^e WILLS EYE HOSPITAL   (United States)

^f Foothills Pharmaceutical Development LLC   (United States)

Author keywords

cornea; cornea verticillata; epithelium; ocular side effects; vortex keratopathy; whorl keratopathy

Indexed keywords

AMIODARONE; AMODIAQUINE; ATOVAQUONE; CHLOROQUINE; CHLORPROMAZINE; CIPROFLOXACIN; CLOFAZIMINE; CYTARABINE; GENTAMICIN; GOLD SALT; HYDROXYCHLOROQUINE; IBUPROFEN; INDOMETACIN; MEPACRINE; MONOBENZONE; NAPROXEN; OSIMERTINIB; PERHEXILINE MALEATE; SURAMIN; TAFENOQUINE; TAMOXIFEN; TILORONE; TOBRAMYCIN; TRASTUZUMAB EMTANSINE; VANDETANIB;

CATARACT; CELL MIGRATION; COLOR VISION DEFECT; CONJUNCTIVA DISEASE; CONJUNCTIVITIS; CORNEA DISEASE; CORNEA DYSTROPHY; CORNEA EDEMA; CORNEA EPITHELIUM; CORNEA EROSION; CORNEA PERFORATION; CORNEA ULCER; CRYOGLOBULINEMIA; CYSTINOSIS; DIABETES MELLITUS; DIFFERENTIAL DIAGNOSIS; FABRY DISEASE; GOUT; HUMAN; KERATOCONJUNCTIVITIS; KERATOCONJUNCTIVITIS SICCA; KERATOPATHY; LIPIDOSIS; MACULAR EDEMA; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; NEURITIS; OPTIC NERVE DISEASE; OPTIC NEURITIS; PAPILLEDEMA; PARAPROTEINEMIA; PATHOPHYSIOLOGY; PATIENT COUNSELING; PATIENT MONITORING; REFRACTION ERROR; RETINA MACULOPATHY; RETINOPATHY; REVIEW; SUBCAPSULAR CATARACT; VISUAL ACUITY; WALDENSTROEM MACROGLOBULINEMIA; CHEMICALLY INDUCED; DRUG EFFECTS; PATHOLOGY;

CORNEAL DISEASES; EPITHELIUM, CORNEAL; HUMANS;

EID: 85013106434     PISSN: 00396257     EISSN: 18793304     Source Type: Journal    
DOI: 10.1016/j.survophthal.2016.11.008     Document Type: Review

References (90)

1. 1 Agarwal, A., Soliman, M.K., Sepah, Y.J., et al. Diabetic retinopathy: variations in patient therapeutic outcomes and pharmacogenomics. Pharmgenomics Pers Med 7 (2014), 399–409.
2. 2 Ahn, J., Wee, W.R., Lee, J.H., Hyon, J.Y., Vortex keratopathy in a patient receiving vandetanib for non-small cell lung cancer. Korean J Ophthalmol 25:5 (2011), 355–357.
3. 3 Alexander, L.J., Bowerman, L., Thompson, L.R., The prevalence of the ocular side effects of chlorpromazine in the Tuscaloosa Veterans Administration patient population. J Am Optom Assoc 56:11 (1985), 872–876.
4. 4 Anderson, N., Borlak, J., Drug-induced phospholipidosis. FEBS Lett 580:23 (2006), 5533–5540.
5. 5 Barot, R.K., Viswanath, V., Pattiwar, M.S., Torsekar, R.G., Crystalline deposition in the cornea and conjunctiva secondary to long-term clofazimine therapy in a leprosy patient. Indian J Ophthalmol 59:4 (2011), 328–329.
6. 6 Bernstein, H.N., Some iatrogenic ocular diseases from systemically administered drugs. Int Ophthalmol Clin 10:3 (1970), 553–619.
7. 7 Bron, A.J., McLendon, B.F., Camp, A.V., Epithelial deposition of gold in the cornea in patients receiving systemic therapy. Am J Ophthalmol 88:3 Pt 1 (1979), 354–360.
8. 8 Burch, T.A., Ashburn, L.L., Experimental therapy of onchocerciasis with suramin and hetrazan; results of a three-year study. Am J Trop Med Hyg 31:5 (1951), 617–623.
9. 9 Chia, P.L., John, T., Vortex keratopathy presumed secondary to AZD9291. J Thorac Oncol 10:12 (2015), 1807–1808.
10. 10 Chong, E.M., Campbell, R.J., Bourne, W.M., Vortex keratopathy in a patient with multiple myeloma. Cornea 16:5 (1997), 592–594.
11. 11 D'Amico, D.J., Kenyon, K.R., Drug-induced lipidoses of the cornea and conjunctiva. Int Ophthalmol 4:1–2 (1981), 67–76.
12. 12 D'Amico, D.J., Kenyon, K.R., Ruskin, J.N., Amiodarone keratopathy: drug-induced lipid storage disease. Arch Ophthalmol 99:2 (1981), 257–261.
13. 13 Davey, P.G., Fabry disease—ocular manifestations and visual symptoms. Davey, P.G., (eds.) Ophthalmology - Current Clinical and Research Updates, 2014, InTech, Rijeka, Croatia, 385–393.
14. 14 Dorrell, L., Ellerton, C., Cottrell, D.G., Snow, M.H., Toxicity of clarithromycin in the treatment of Mycobacterium avium complex infection in a patient with AIDS. J Antimicrob Chemother 34:4 (1994), 605–606.
15. 15 Dosso, A., Rungger-Brändle, E., In vivo confocal microscopy in hydroxychloroquine-induced keratopathy. Graefes Arch Clin Exp Ophthalmol 245:2 (2007), 318–320.
16. 16 Dua, H.S., Singh, A., Gomes, J.A., et al. Vortex or whorl formation of cultured human corneal epithelial cells induced by magnetic fields. Eye (Lond) 10:Pt 4 (1996), 447–450.
17. 17 Dua, H.S., Watson, N.J., Mathur, R.M., Forrester, J.V., Corneal epithelial cell migration in humans: ‘hurricane and blizzard keratopathy’. Eye (Lond) 7:Pt 1 (1993), 53–58.
18. 18 Eaton, J.S., Miller, P.E., Mannis, M.J., Murphy, C.J., Ocular adverse events associated with antibody-drug conjugates in human clinical trials. J Ocul Pharmacol Ther 31:10 (2015), 589–604.
19. 19 Eng, C.M., Germain, D.P., Banikazemi, M., et al. Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med 8:9 (2006), 539–548.
20. 20 Fitt, A., Dayan, M., Gillie, R.F., Vortex keratopathy associated with ibuprofen therapy. Eye (Lond) 10:Pt 1 (1996), 145–146.
21. 21 Florence, A.T., Attwood, D., (eds.) Physicochemical Principles of Pharmacy in Manufacture, Formulation and Clinical Use, 2015, Pharmaceutical Press, London, England.
22. 22 Fraunfelder, F.W., Corneal toxicity from topical ocular and systemic medications. Cornea 25:10 (2006), 1133–1138.
23. 23 Ghosh, M., McCulloch, C., Amiodarone-induced ultrastructural changes in human eyes. Can J Ophthalmol 19:4 (1984), 178–186.
24. 24 Gibson, J.M., Fielder, A.R., Garner, A., Millac, P., Severe ocular side effects of perhexilene maleate: case report. Br J Ophthalmol 68:8 (1984), 553–560.
25. 25 Gokulgandhi, M.R., Vadlapudi, A.D., Mitra, A.K., Ocular toxicity from systemically administered xenobiotics. Expert Opin Drug Metab Toxicol 8:10 (2012), 1277–1291.
26. 26 Graham, C.M., Blach, R.K., Indomethacin retinopathy: case report and review. Br J Ophthalmol 72:6 (1988), 434–438.
27. 27 Greiner, A.C., Berry, K., Skin pigmentation and corneal and lens opacities with prolonged chlorpromazine therapy. Can Med Assoc J 90 (1964), 663–665.
28. 28 Guthoff, T., Tietze, B., Meinhardt, B., et al. Cytosine-arabinoside-induced keratopathy: a model of corneal proliferation kinetics. Ophthalmologica 224:5 (2010), 308–311.
29. 29 Halliwell, W.H., Cationic amphiphilic drug-induced phospholipidosis. Toxicol Pathol 25:1 (1997), 53–60.
30. 30 Hedges, T.R. 3rd, Kenyon, K.R., Hanninen, L.A., Mosher, D.B., Corneal and conjunctival effects of monobenzone in patients with vitiligo. Arch Ophthalmol 101:1 (1983), 64–68.
31. 31 Hemady, R.K., Sinibaldi, V.J., Eisenberger, M.A., Ocular symptoms and signs associated with suramin sodium treatment for metastatic cancer of the prostate. Am J Ophthalmol 121:3 (1996), 291–296.
32. 32 Holland, E.J., Stein, C.A., Palestine, A.G., et al. Suramin keratopathy. Am J Ophthalmol 106:2 (1988), 216–220.
33. 33 Hollander, D.A., Aldave, A.J., Drug-induced corneal complications. Curr Opin Ophthalmol 15:6 (2004), 541–548.
34. 34 Hostetler, K.Y., Hall, L.B., Inhibition of kidney lysosomal phospholipases A and C by aminoglycoside antibiotics: possible mechanism of aminoglycoside toxicity. Proc Natl Acad Sci U S A 79:5 (1982), 1663–1667.
35. 35 Iaccheri, B., Fiore, T., Papadaki, T., et al. Adverse drug reactions to treatments for ocular toxoplasmosis: a retrospective chart review. Clin Ther 30:11 (2008), 2069–2074.
36. 36 Ingram, D.V., Jaggarao, N.S., Chamberlain, D.A., Ocular changes resulting from therapy with amiodarone. Br J Ophthalmol 66:10 (1982), 676–679.
37. 37 Johnson, L.N., Krohel, G.B., Thomas, E.R., The clinical spectrum of amiodarone-associated optic neuropathy. J Natl Med Assoc 96:11 (2004), 1477–1491.
38. 38 Kaufmann, A.M., Krise, J.P., Lysosomal sequestration of amine-containing drugs: analysis and therapeutic implications. J Pharm Sci 96:4 (2007), 729–746.
39. 39 Klintworth, G.K., Corneal dystrophies. Orphanet J Rare Dis, 4, 2009, 7.
40. 40 Kremer, I., Wright, P., Merin, S., et al. Corneal subepithelial monoclonal kappa IgG deposits in essential cryoglobulinaemia. Br J Ophthalmol 73:8 (1989), 669–673.
41. 41 Lal, S., Bloom, D., Silver, B., et al. Replacement of chlorpromazine with other neuroleptics: effect on abnormal skin pigmentation and ocular changes. J Psychiatry Neurosci 18:4 (1993), 173–177.
42. 42 Lemp, M.A., Mathers, W.D., Corneal epithelial cell movement in humans. Eye (Lond) 3:Pt 4 (1989), 438–445.
43. 43 Leung, A.T., Cheng, A.C., Chan, W.M., Lam, D.S., Chlorpromazine-induced refractile corneal deposits and cataract. Arch Ophthalmol 117:12 (1999), 1662–1663.
44. 44 Lin, J., Zhao, G.Q., Che, C.Y., et al. Characteristics of ocular abnormalities in gout patients. Int J Ophthalmol 6:3 (2013), 307–311.
45. 45 Lisch, W., Büttner, A., Oeffner, F., et al. Lisch corneal dystrophy is genetically distinct from Meesmann corneal dystrophy and maps to xp22.3. Am J Ophthalmol 130:4 (2000), 461–468.
46. 46 Lochhead, J., Salmon, J.F., Bron, A.J., Cytarabine-induced corneal toxicity. Eye (Lond) 17:5 (2003), 677–678.
47. 47 López, J.D., del Castillo, J.M., López, C.D., Sánchez, J.G., Confocal microscopy in ocular chrysiasis. Cornea 22:6 (2003), 573–575.
48. 48 Lowe, R., Mussa, H.Y., Nigsch, F., et al. Predicting the mechanism of phospholipidosis. J Cheminform, 4, 2012, 2.
49. 49 Mäntyjärvi, M., Tuppurainen, K., Ikäheimo, K., Ocular side effects of amiodarone. Surv Ophthalmol 42:4 (1998), 360–366.
50. 50 Marmor, M.F., Kellner, U., Lai, T.Y., et al. American Academy of Ophthalmology. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology 123:6 (2016), 1386–1394.
51. 51 Martínez-Costa, L., Victoria Ibañez, M., Murcia-Bello, C., et al. Use of microperimetry to evaluate hydroxychloroquine and chloroquine retinal toxicity. Can J Ophthalmol 48:5 (2013), 400–405.
52. 52 Milman, T., Kao, A.A., Chu, D., et al. Paraproteinemic keratopathy: the expanding diversity of clinical and pathologic manifestations. Ophthalmology 122:9 (2015), 1748–1756.
53. 53 Murphy, M.A., Murphy, J.F., Amiodarone and optic neuropathy: the heart of the matter. J Neuroophthalmol 25:3 (2005), 232–236.
54. 54 Nasveld, P.E., Edstein, M.D., Reid, M., et al., Tafenoquine Study Team. Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects. Antimicrob Agents Chemother 54:2 (2010), 792–798.
55. 55 Nayfield, S.G., Gorin, M.B., Tamoxifen-associated eye disease. A review. J Clin Oncol 14:3 (1996), 1018–1026.
56. 56 Neubauer, A.S., Samari-Kermani, K., Schaller, U., et al. Detecting chloroquine retinopathy: electro-oculogram versus colour vision. Br J Ophthalmol 87:7 (2003), 902–908.
57. 57 Noureddin, B.N., Seoud, M., Bashshur, Z., et al. Ocular toxicity in low-dose tamoxifen: a prospective study. Eye (Lond) 13:Pt 6 (1999), 729–733.
58. 58 Orlando, R.G., Dangel, M.E., Schaal, S.F., Clinical experience and grading of amiodarone keratopathy. Ophthalmology 91:10 (1984), 1184–1187.
59. 59 Orssaud, C., Dufier, J., Germain, D., Ocular manifestations in Fabry disease: a survey of 32 hemizygous male patients. Ophthalmic Genet 24:3 (2003), 129–139.
60. 60 Paladini, I., Menchini, U., Mencucci, R., Corneal chrysiasis: in vivo confocal microscopy analysis. Eur J Ophthalmol 20:4 (2010), 776–779.
61. 61 Passman, R.S., Bennett, C.L., Purpura, J.M., et al. Amiodarone-associated optic neuropathy: a critical review. Am J Med 125:5 (2012), 447–453.
62. 62 Pavlidis, N.A., Petris, C., Briassoulis, E., et al. Clear evidence that long-term, low-dose tamoxifen treatment can induce ocular toxicity. A prospective study of 63 patients. Cancer 69:12 (1992), 2961–2964.
63. 63 Piret, J., Kishore, B.K., Tulkens, P.M., Effect of substrate organization on the activity and on the mechanism of gentamicin-induced inhibition of rat liver lysosomal phospholipase A1. Biochem Pharmacol 43:4 (1992), 895–898.
64. 64 Reasor, M.J., Hastings, K.L., Ulrich, R.G., Drug-induced phospholipidosis: issues and future directions. Expert Opin Drug Saf 5:4 (2006), 567–583.
65. 65 Santos-Bueso, E., Ahmed-Wasfy, M., Sáenz-Francés, F., et al. [Corneal chrysiasis. Gold salt deposits in the cornea in a patient with rheumatoid arthritis. An analysis with confocal microscopy]. Arch Soc Esp Oftalmol 88:6 (2013), 237–239.
66. 66 Sawada, H., Takami, K., Asahi, S., A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system. Toxicol Sci 83:2 (2005), 282–292.
67. 67 Shah, G.K., Cantrill, H.L., Holland, E.J., Vortex keratopathy associated with atovaquone. Am J Ophthalmol 120:5 (1995), 669–671.
68. 68 Sharma, P., Madi, H.A., Bonshek, R., Morgan, S.J., Cloudy corneas as an initial presentation of multiple myeloma. Clin Ophthalmol 8 (2014), 813–817.
69. 69 Shayman, J.A., Abe, A., Drug induced phospholipidosis: an acquired lysosomal storage disorder. Biochim Biophys Acta 1831:3 (2013), 602–611.
70. 70 Srinivasan, S., Shehadeh-Mashor, R., Slomovic, A.R., Corneal manifestations of metabolic diseases. Krachmer, J.H., Mannis, M.J., Holland, E.J., (eds.) Cornea, ed 2, 2011, Elsevier Mosby, Philadelphia, 665–690.
71. 71 Stein, C.A., LaRocca, R.V., Thomas, R., et al. Suramin: an anticancer drug with a unique mechanism of action. J Clin Oncol 7:4 (1989), 499–508.
72. 72 Szmyd, L. Jr., Perry, H.D., Keratopathy associated with the use of naproxen. Am J Ophthalmol, 99(5), 1985, 598.
73. 73 Teich, S.A., Handwerger, S., Mathur-Wagh, U., et al. Toxic keratopathy associated with suramin therapy. N Engl J Med 314:22 (1986), 1455–1456.
74. 74 Thompson, A.M., Ocular toxicity of fluoroquinolones. Clin Exp Ophthalmol 35:6 (2007), 566–577.
75. 75 Thylefors, B., Rolland, A., The risk of optic atrophy following suramin treatment of ocular onchocerciasis. Bull World Health Organ 57:3 (1979), 479–480.
76. 76 Tyagi, A.K., Kayarkar, V.V., McDonnell, P.J., An unreported side effect of topical clarithromycin when used successfully to treat Mycobacterium avium-intracellulare keratitis. Cornea 18:5 (1999), 606–607.
77. 77 Ufuk, A., Somers, G., Houston, J.B., Galetin, A., In vitro assessment of uptake and lysosomal sequestration of respiratory drugs in alveolar macrophage cell line NR8383. Pharm Res 32:12 (2015), 3937–3951.
78. 78 Vassallo, P., Trohman, R.G., Prescribing amiodarone: an evidence-based review of clinical indications. JAMA 298:11 (2007), 1312–1322.
79. 79 Vijay Zawar, S., Mahadik, S., Corneal deposit after topical ciprofloxacin as postoperative medication after cataract surgery. Can J Ophthalmol 49:4 (2014), 392–394.
80. 80 Wålinder, P.E., Gip, L., Stempa, M., Corneal changes in patients treated with clofazimine. Br J Ophthalmol 60:7 (1976), 526–528.
81. 81 Wasielica-Poslednik, J., Pfeiffer, N., Reinke, J., Pitz, S., Confocal laser-scanning microscopy allows differentiation between Fabry disease and amiodarone-induced keratopathy. Graefes Arch Clin Exp Ophthalmol 249:11 (2011), 1689–1696.
82. 82 Wilson, F.M. 2nd, Adverse external ocular effects of topical ophthalmic therapy: an epidemiologic, laboratory, and clinical study. Trans Am Ophthalmol Soc 81 (1983), 854–965.
83. 83 Yeh, S., Fine, H.A., Smith, J.A., Corneal verticillata after dual anti-epidermal growth factor receptor and anti-vascular endothelial growth factor receptor 2 therapy (vandetanib) for anaplastic astrocytoma. Cornea 28:6 (2009), 699–702.
84. 84 Yip, V.C., Sanjay, S., Corneal manifestations of chronic systemic drug therapy. J Clin Exp Ophthalmol, 2(1), 2011.
85. 85 Yoon, J.J., Ismail, S., Sherwin, T., Limbal stem cells: central concepts of corneal epithelial homeostasis. World J Stem Cells 6:4 (2014), 391–403.
86. A Kadcyla (ado-trastuzumab emtansine) for injection, for intravenous use, 2013, Genentech, South San Francisco (CA) Package insert.
87. B Klintworth, G., Orphanet: Lisch epithelial corneal dystrophy. Orphanet [Internet]. 2012 Available at: http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN&Expert=98955 Accessed September 21, 2016.
88. C Moskowitz, C.H., Fanale, M.A., Shah, B.D., et al. A phase 1 study of denintuzumab mafodotin (SGN-CD19A) in relapsed/refractory B-lineage non-Hodgkin lymphoma [abstract]. Blood, 126(23), 2015, 182.
89. D Sadrieh, N., Reasor, M., Hsieh, F., et al. The regulatory challenges of drug-induced phospholipidosis. ACPS meeting, April 14, 2010, 2010, U.S. Food and Drug Administration, Silver Spring (MD) Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AdvisoryCommitteeforPharmaceuticalScienceandClinicalPharmacology/UCM210798.pdf Accessed August 25, 2016.
90. E Thompson, J.A., Motzer, R., Molina, A.M., et al. Phase I studies of antiENPP3 antibody drug conjugates (ADCs) in advanced refractory renal cell carcinomas (RRCC) [abstract]. J Clin Oncol, 33(15 Suppl), 2015, 2503.